Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I am
Thanks , so much for your reply. That’s a poor ! have looked at the following link . The poster seems to have gone .it was downloadable ?
Sorry I can’t go either however also wish to ask some questions . We should perhaps prepare a list ?
I can’t seem to find the poster from the link :
The abstract of the presentation will be made available on Scancell's website at: https://www.scancell.co.uk/vaccine-publications
The abstract of the presentation will be made available on Scancell's website at: https://www.scancell.co.uk/vaccine-publications
Dr Stewart Sale
Sales & Business Development Professional #creativethinker #problemsolver
Posted this on his LinkedIn page
Looking forward to attend the OBN (UK) Ltd #IversenBuilding launch event at the The Oxford Science Park next Wednesday (15th Nov).
https://obn.glueup.com/event/the-oxford-science-park-iversen-building-launch-event-91550/
Would be great to catch up with some of the researchers from the companies based on site at the Science Park - Evox Therapeutics Ltd T-Cypher Bio Sitryx Scancell Ltd Enara Bio Exscientia JUNO Genetics EU Ochre Bio OxSonics Therapeutics Oxular ProImmune Theolytics Nucleome Therapeutics Oxford BioTherapeutics OXGENE MiroBio Ltd - drop me a message if you are around and free to meet
Would be his dream ......To mato with a big pharma
Morning , mentioned yesterday the Cell therapy being evaluated. I found this question and answer session informative on the discussion of cell Therapy from Bristol Myers Squidd , informative
https://www.bms.com/life-and-science/science/discussing-the-future-of-cancer-treatments-using-cell-therapy.html?linkId=248244746
Ignore the BMS sentence because I the could not find the link sorry
I imagine the Presentation was well recieved . Wish to point out the following paragraph from the July 10th pipeline . I am just wondering how the 6 month evaluation is going ? "a NEW 6-month evaluation by a leading Biotech company."
find full paragraph as a remember ? Bristol Myers Squid made a anouncement
"Scancell has developed a novel technology platform for producing monoclonal antibodies that recognise glycans with high specificity and affinity. The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023."
I agree with you all . The frustration of the communication. Etc . Find it astonishing they Rns a poster but not an actual speaker slot ? As is happening today
Good to all patience is indeed tested ! Also missing AGM in NYC
SYNONYMS FOR
trailblazing :
innovative
revolutionary
avant-garde
radical
cutting-edge
innovating
leading-edge
spearheading
trendsetting
Busy week
TUESDAY, 14 NOVEMBER
Glycan and Novel Targets for Bispecific Cancer Therapy
Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, Ltd.
Antibody therapy based on glycan targets remains attractive. We will present preclinical results from reformatting these antibodies to T cell redirecting bispecifics, ADC, as well as their potential for CAR therapy; showcasing their versatility. Combination therapy may be warranted for optimising their efficacy towards solid tumours.
Wednesday 15th Of November
Dr Stewart Sale
Sales & Business Development Professional #creativethinker #problemsolver
Posted this on his LinkedIn page
Looking forward to attend the OBN (UK) Ltd #IversenBuilding launch event at the The Oxford Science Park next Wednesday (15th Nov).
https://obn.glueup.com/event/the-oxford-science-park-iversen-building-launch-event-91550/
Would be great to catch up with some of the researchers from the companies based on site at the Science Park - Evox Therapeutics Ltd T-Cypher Bio Sitryx Scancell Ltd Enara Bio Exscientia JUNO Genetics EU Ochre Bio OxSonics Therapeutics Oxular ProImmune Theolytics Nucleome Therapeutics Oxford BioTherapeutics OXGENE MiroBio Ltd - drop me a message if you are around and free to meet.
SOCIETY FOR MELANOMA RESEARCH
https://smrcongress.org/agenda-thurs-9
10:30am - 12:00pm
PLENARY SESSION 10 - Late Breaking Clinical Abstracts
Salon A-F
Session Chairs: Sapna Patel
Session available virtually
10:30am - 10:45am
15 Mins
DREAMseq (EA6134): a Phase III Trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM): Final 2-year OS Data and Biomarkers
Michael Atkins
10:45am - 11:00am
15 Mins
Lenvatinib plus pembrolizumab (len + pembro) versus pembro alone for unresectable or metastatic melanoma (MEL): results of LEAP-003
Ana Arance
11:00am - 11:15am
15 Mins
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab+ ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE trial
Fayaz Master
11:15am - 11:30am
15 Mins
A Phase I/II Study of DYP688, an Antibody Drug Conjugate Delivering a Direct Gq/11 Inhibitor in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Matteo Carlino
11:30am - 11:45am
15 Mins
Combined inhibition of MEK1/2 plus Autophagy in Metastatic/Locally Advanced, Unresectable NRAS-Mutated Melanoma: A Phase Ib/II trial of trametinib plus hydroxychloroquine in patients with NRAS-Mutated Melanoma (CHLORO TRAM MEL, NCT03979651)
Amelie Boespflug
12:00pm - 12:10pm
Closing Remarks
So right C11
the share prices :
Merck share price $102
BioNtech $99
Moderna share price $69
last but not lease the bargain basement once in a lifetime "derisory " share price of
Scancell £ 0.15
it really is bonkers , come on New PR and business development do your thing . Wonder why the poster was kept under wraps so long after conference finished . one would think big pharmas will be all over it ?
Find the link for the poster NOW on Scancell page
TITLE
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), 1-5 November 2023 in San Diego, CA, USA
https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/2023/sitc_scope-study-poster_october-23_final.pdf
Part 2
link to the poster
Find the link for the poster NOW on Scancell page
TITLE
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), 1-5 November 2023 in San Diego, CA, USA
https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/2023/sitc_scope-study-poster_october-23_final.pdf
Thanks Markus 2 ADVFN for conclusion and summary of the poster and further advances of iSCIB1+ second generation technology is the next best thing :
find the BionTech offering
BioNtech share price $99
https://www.pharmaceutical-technology.com/data-insights/bnt-121-biontech-melanoma-likelihood-of-approval/
Re their offering of CTLA-4-pretreated advanced or metastatic melanoma.
As a follow-up to the data recently presented at ESMO, BioNTech will give an update on the first-in-human Phase 1 study with BNT221 (NCT04625205), a personalized, autologous neoantigen-specific T cell therapy, which is being evaluated in patients with anti-PD-1- and anti-CTLA-4-pretreated advanced or metastatic melanoma. The data update includes nine patients. Seven of these patients have stable disease with shrinkage of tumor lesions in four of these patients. The initial results show a manageable safety profile with no dose limiting toxicities. In addition, preliminary translational data show multiple functional neoantigen-specific T cell responses in all evaluable patients.
Compare and contrast , Scancell V Moderna V Biontech ?
Melanoma vaccines .
Scancell share price £ 0.12
Conclusions as Mark
SCIB1 is well tolerated, and the ORR efficacy data of
82% in the first stage of cohort 1 is highly encouraging.
This level of effectiveness in the combination setting
has trailblazing potential for the ImmunoBody®
platform in further improving the survival rates in
patients with unresectable melanoma. This study is
ongoing, and a phase 2/3 registration study is currently
under planning.
iSCIB1+ second generation technology is the next best thing :
► No HLA screening, can access 100% of the addressable market
► AvidiMab® modification increases potency and gives 15 years extended patent protection
► Very little risk of iSCIB1+ not working as it the same as SCIB1 but with more epitopes expressed by melanoma
► A study amendment has been submitted to the MRHA to add a new cohort of iSCIB1+ patients to the SCOPE trial
Press release Join effort https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
Moderna share price $69
Merck share price $102
mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Companies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types
CAMBRIDGE, MA and RAHWAY, NJ/ ACCESSWIRE / December 13, 2022 / Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p value=0.0266) compared with KEYTRUDA alone.
BioNtech share price $99
https://www.pharmaceutical-technology.com/data-insights/bnt-121-biontech-melanoma-likelihood-of-approval/
Re their offering of CTLA-4-pretreated advanced or metastatic melanoma.
As a fo
That's excellent ... "trailblazing" is indeed quite a statement . well done scancel
What we do know is that Scancell has close connections with both Genmab and BioNTech
So I found this interesting to look at the Genmab pipeline and also the BionTech press release for SITC
Biontech press release for SITC ,
Who have partnered with Genmab
https://www.genmab.com/pipeline/
https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-and-preclinical-data-updates-across
Re their offering of CTLA-4-pretreated advanced or metastatic melanoma.
“As a follow-up to the data recently presented at ESMO, BioNTech will give an update on the first-in-human Phase 1 study with BNT221 (NCT04625205), a personalized, autologous neoantigen-specific T cell therapy, which is being evaluated in patients with anti-PD-1- and anti-CTLA-4-pretreated advanced or metastatic melanoma. The data update includes nine patients. Seven of these patients have stable disease with shrinkage of tumor lesions in four of these patients. The initial results show a manageable safety profile with no dose limiting toxicities. In addition, preliminary translational data show multiple functional neoantigen-specific T cell responses in all evaluable patients.”
🤔 ?
Morning I posted this a few days ago
PEGS Europe starts 14 th of November as I mentioned earlier. Scancell are talking first at 14.40 on the subject the topic is :
Glycan and Novel Targets for Bispecific Cancer Therapy
Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, Ltd. Will be delivering followed by
At 15 . 10 pm by Genmab
Rob N. de Jong, PhD, Senior Director and Head, Antibody Format Development, Genmab
am sure they will be discussing the pipeline and Glymab
Just in case anyone missed it
Antibody therapy based on glycan targets remains attractive. We will present preclinical results from reformatting these antibodies to T cell redirecting bispecifics, ADC, as well as their potential for CAR therapy; showcasing their versatility. Combination therapy may be warranted for optimising their efficacy towards solid tumours.
15:10 Gennab follows
HexElect: Logic-Gated Antibody Pairs That Selectively Act on Cells Co-Expressing Two Antigens
Rob N. de Jong, PhD, Senior Director and Head, Antibody Format Development, Genmab BV
We have developed mutually-dependent IgG antibody combinations engineered to selectively act on cells co-expressing two antigens. Genmab’s HexElect technology is based on Fc-domain engineered IgG antibody pairs that act as Bio-Logic AND gates selectively activated after hetero-oligomerization. Functional activation of complement or signaling by HexElect antibody pairs was stringently dependent on the presence of two targets co-expressed at the same cell surface. HexElect technology may enable access to an untapped, combinatorial target space for the generation of antibody therapeutics that exhibit both selectivity and potency.
Many thanks BOJO excellent post and perspective